Related Experiment Video

Updated: Aug 14, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin

H Wehbe1, C M Kearney, K G Pinney

  • 1Department of Biology, Institute of Biomedical Studies, Center for Drug Discovery, Baylor University, Waco, TX 76798, USA.

Anticancer Research
|November 29, 2005
PubMed

Insights

Drug resistance in non-small cell lung cancer cells is linked to changes in beta-tubulin isotypes. Alterations in class III beta-tubulin were observed in cells resistant to anti-cancer drugs like paclitaxel and combretastatin A-4.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tubulin isotype distribution is implicated in anti-cancer drug resistance and efficacy.
  • Understanding these mechanisms is crucial for developing more effective cancer therapies.
  • Non-small cell lung carcinoma (NSCLC) is a major cause of cancer-related mortality.

Purpose of the Study:

  • To investigate the role of tubulin isotype alterations in the development of drug resistance in NSCLC cells.
  • To compare the development of resistance to different classes of anti-tubulin agents.
  • To characterize the specific tubulin isotype changes associated with resistance to combretastatin A-4 (CA4), paclitaxel, and vinblastine.

Main Methods:

  • Establishing drug-resistant NSCLC H460 cell lines through stepwise selection with CA4, paclitaxel, or vinblastine.
  • Utilizing Western blot analysis to assess changes in total beta-tubulin and specific tubulin isotypes (classes I, III, and IV).
  • Comparing the rate of resistance development between different drug treatments.

Main Results:

  • The rate of resistance development to CA4 was slower compared to paclitaxel.
  • Western analysis revealed significant alterations in total beta-tubulin and tubulin isotypes I, III, and IV in resistant cell lines.
  • Class III beta-tubulin showed significant alterations across all resistant cell lines, with increased expression in paclitaxel-resistant cells and reduced expression in CA4- and vinblastine-resistant cells.

Conclusions:

  • This study provides the first evidence of resistance development to combretastatins in NSCLC cells.
  • Changes in tubulin isotype expression, particularly class III beta-tubulin, are associated with resistance to microtubule-targeting agents.
  • Differential alterations in class III beta-tubulin expression correlate with the mechanism of action (stabilizer vs. destabilizer) of the anti-cancer drugs.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...